A GPS peroxisome delivery inhibitory peptide and its application in the treatment of vascular calcification
By using generative AI-designed AGPS peroxisome delivery inhibitory peptide Pep391, which binds to the PTS2 domain of AGPS, the translocation of AGPS to the peroxisome is blocked, solving the problem of uncontrollable vascular calcification progression in existing technologies and achieving a significant reduction in vascular calcification and calcium salt deposition.
Patent Information
- Application Number
- CN202611638393.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-22
- Publication Date
- 2026-11-17
AI Technical Summary
Existing intervention strategies have failed to effectively prevent or reverse the progression of vascular calcification and face poor compliance, adverse reactions, and the mineralization paradox. The process of targeting peroxisome cargo protein delivery has not been fully explored.
A peroxisome translocation inhibitory peptide Pep391 for AGPS was designed. This peptide, consisting of 58 amino acids generated by generative artificial intelligence (AI), binds to the PTS2 domain of AGPS, blocking the translocation of AGPS to the peroxisome. It is then administered intravenously for the treatment of vascular calcification.
It significantly reduces vascular calcification, decreases vascular calcium salt deposition and RUNX2 and BGLAP expression, and has independent cardiovascular protective value, without relying on improving renal function or reducing renal fibrosis.
Smart Images

Figure CN123106848A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology and relates to an AGPS peroxisome delivery inhibitory peptide designed de novo using artificial intelligence, its pharmaceutical composition, and its application in the preparation of drugs for the prevention or treatment of vascular calcification. Background Technology
[0002] Vascular calcification is a common complication of atherosclerosis, hypertension, diabetes, and aging, and a major driver of cardiovascular death in patients with chronic kidney disease (CKD). Characterized by hydroxyapatite deposition in the arterial media, it leads to increased arterial stiffness, widened pulse pressure, and left ventricular hypertrophy. In addition to traditional risk factors, CKD patients also experience additional non-traditional risk factors such as hyperphosphatemia, oxidative stress, inflammation, and decreased levels of vascular calcification inhibitors (e.g., pyrophosphate, fetoglobulin-A, and matrix Gla protein), resulting in earlier and faster progression of media calcification. Transdifferentiation of vascular smooth muscle cells (VSMCs) into an osteoblastic phenotype is a core cellular event driving media calcification, manifested by the loss of contractile markers (e.g., α-SMA, SM22α) and the upregulation of osteogenic markers (e.g., RUNX2, BGLAP, ALP), ultimately leading to calcium deposition in the elastic lamellae.
[0003] Current intervention strategies for vascular calcification mainly focus on the regulation of systemic calcium and phosphorus metabolism, including phosphate binders, calcimenoplastins, and active vitamin D analogs, as well as pyrophosphate derivatives targeting hydroxyapatite formation. However, these interventions have largely failed to consistently halt or reverse the progression of medial calcification in clinical trials and face challenges such as poor adherence, adverse reactions, and the "mineralization paradox" (i.e., the potential to impair bone mineralization while inhibiting vascular calcification). Emerging strategies, such as the TNAP-targeting inhibitor SBI-425, the epigenetic regulator apabetalone, SGLT2 inhibitors, and calprotectin blockers, are mostly still in the preclinical stage, and their clinical translation potential remains to be validated. Notably, existing strategies do not target the peroxisome cargo protein delivery process, whose pathological role in VSMC metabolic reprogramming has long been overlooked.
[0004] Peroxisomes are key organelles for reactive oxygen species (ROS) scavenging and lipid metabolism. Ether lipids are a unique class of glycerophospholipids synthesized in peroxisomes, with their biosynthetic pathway synergistically mediated by AGPS, GNPAT, and FAR1, where AGPS catalyzes the rate-limiting step. The enzymatic activity of AGPS is strictly dependent on its efficient translocation to the peroxisome, a process guided by its N-terminal PTS2 signal (core nonapeptide motif RLRVLSGHL): PEX7, acting as a cytoplasmic receptor, recognizes PTS2 cargo, and with the participation of cofactors such as PEX39, the cargo protein is introduced into the peroxisome via a membrane translocation channel formed by PEX13. Recent studies have found a close correlation between abnormal ether lipid metabolism and ferroptosis sensitivity—ether lipids can provide substrates for lipid peroxidation, thereby promoting ferroptosis. Ferroptosis has been shown to participate in the pathological process of vascular calcification, but how peroxisome ether lipid metabolism connects metabolic reprogramming with VSMC ferroptosis and calcification has not been previously elucidated.
[0005] Our previous research found that in chronic kidney disease-related vascular calcification, the introduction of AGPS into peroxisomes is significantly enhanced, depending on the binding of PKCη (a serine / threonine protein kinase encoded by the PRKCH gene) to AGPS-PTS2. Using small molecule peptides to bind AGPS-PTS2 can significantly reduce the introduction of AGPS into peroxisomes and also alleviate vascular calcification. Therefore, interfering with the function of AGPS-PTS2 is an effective way to treat chronic kidney disease-related vascular calcification.
[0006] At the drug design level, the development of peptide drugs targeting protein-protein interactions (PPIs) faces challenges due to the limited candidate space, long development cycles, and difficulty in balancing structural stability and target-interface complementarity inherent in traditional screening methods (natural ligand fragments, phage display, or large-scale experimental screening). In recent years, generative artificial intelligence protein design technologies have made breakthroughs. Models such as RFdiffusion can generate peptide backbones de novo around a pre-defined target surface. Combined with AlphaFold3 complex structure prediction and Rosetta energy evaluation, this can rapidly narrow down the validation pool from a large number of candidate sequences. However, there is no precedent for applying this technology to the design of interventional peptides in the peroxisome cargo protein delivery process. Summary of the Invention
[0007] Vascular calcification is a common complication of atherosclerosis, hypertension, diabetes, and aging. It is also an independent risk factor for increased cardiovascular events and mortality in patients with chronic kidney disease (CKD). The metabolic changes leading to vascular calcification are not fully understood. Therefore, this invention proposes an AGPS peroxisome translocation inhibitory peptide and its application in the prevention or treatment of vascular calcification. The inhibitory peptide works by binding to the PTS2 domain of AGPS, inhibiting the translocation / translocation of AGPS to the peroxisome, thereby reducing vascular calcification.
[0008] To solve the above-mentioned technical problems, the present invention adopts the following technical solution: The applicant's previous research revealed that the aberrant translocation of the lipid synthase AGPS to the peroxisome is a key driver of vascular calcification. This spatial translocation is triggered by the protein PKCη, leading to a surge in specific lipids, which in turn promotes ferroptosis in vascular smooth muscle cells and mineral deposition in blood vessels. To block this destructive process, we used generative artificial intelligence (AI) to design a custom peptide that blocks the interaction between AGPS and PKCη. After systemic delivery, this AI-designed therapeutic peptide successfully prevented the translocation of the AGPS enzyme, blocked the accumulation of toxic lipids, and significantly reduced aortic calcification in CKD mice. This invention reveals a key metabolic triggering mechanism for vascular calcification and highlights the potential of AI-guided nanotherapy strategies in the treatment of vascular diseases.
[0009] In a first aspect, the present invention provides an AGPS peroxisome delivery inhibitory peptide, named Pep391, which consists of 58 amino acids and has the amino acid sequence SCDWCKYNENLVVTGAVDCSLRGWDLRNVRQPVFELLGHTYAIRRVKFSPFHASVLAS, as shown in SEQ ID NO:1.
[0010] Secondly, this invention provides a method for designing an AGPS peroxisome delivery inhibitory peptide. The method includes: generating a candidate peptide backbone for the AGPS PTS2 target sequence using the RFdiffusion model; predicting the complex structure of the candidate peptide with AGPS using AlphaFold3; evaluating the interfacial binding energy using Rosetta; and verifying the binding ability of the inhibitory peptide to the target sequence through biophysical experiments. The amino acid sequence of the target sequence is shown in SEQ ID NO:2.
[0011] Thirdly, the present invention provides a pharmaceutical composition comprising the aforementioned AGPS peroxisome delivery inhibitory peptide and a pharmaceutically acceptable carrier and / or excipient.
[0012] Furthermore, the dosage form of the pharmaceutical composition is an injection.
[0013] Fourthly, the present invention provides the use of the said inhibitory peptide or the said pharmaceutical composition in the preparation of a drug for the prevention or treatment of vascular calcification.
[0014] Furthermore, the vascular calcification is vascular calcification associated with chronic kidney disease.
[0015] Furthermore, the inhibitory peptide reduces osteoblastic transformation of vascular smooth muscle cells and / or vascular calcium deposition by inhibiting the translocation or introduction of AGPS protein from the cytoplasm to the peroxisome.
[0016] The beneficial effects of this invention are: This invention targets the AGPS peroxisome translocation signal PTS2, rather than the enzyme catalytic center, providing a novel intervention strategy to regulate AGPS subcellular localization, avoiding systemic ether lipid homeostasis disturbances that may be caused by traditional enzyme activity inhibitors. The invention utilizes multi-level screening with artificial intelligence to obtain the lead peptide Pep391, which exhibits nanomolar affinity for AGPS-PTS2, effectively inhibiting the translocation / translocation of AGPS from the cytoplasm to the peroxisome. In a mouse model of chronic kidney disease-related vascular calcification, it significantly reduces the aortic calcification area, decreases vascular calcium deposition, and reduces RUNX2 and BGLAP expression. Furthermore, its anti-calcification effect is independent of improving renal function or alleviating renal fibrosis, demonstrating independent cardiovascular protective value.
[0017] This invention is the first to apply generative AI protein design to the development of peroxisome cargo protein delivery inhibitory peptides, providing a new approach for targeted protein-protein interactions and precise intervention in peroxisome-related diseases, and has significant clinical translational potential. Attached Figure Description
[0018] Figure 1 The dose-dependent curves of the binding of three candidate antagonistic peptides to AGPS, as shown by ELISA detection.
[0019] Figure 2 Sensing plot of Pep391 binding to AGPS protein as detected by surface plasmon resonance (SPR) (curve of sensing unit RU changing over time).
[0020] Figure 3 The image shows the thermophoretic binding curve of Pep39 to AGPS-PTS. The binding fraction (-) indicates the proportion of AGPS-PTS2 bound by Peptide 391, where 0 indicates no binding and 1 indicates complete binding.
[0021] Figure 4 This is a schematic diagram of the molecular docking and interaction between the antagonistic peptide Pep391 and the PTS2 domain of the AGPS target protein. Detailed Implementation
[0022] The present invention will now be described in detail with reference to specific embodiments. It should be noted that the specific embodiments described are merely illustrative of the invention, and the scope of protection of the invention is not limited to the following embodiments. Any changes and modifications made to the invention by those skilled in the art without departing from the concept of the invention should fall within the scope of protection of the invention. Furthermore, various experimental operations not described in detail in the embodiments are conventional techniques in the art. For parts not specifically described herein, those skilled in the art can refer to various commonly used reference books, scientific and technological documents, or related instructions and manuals prior to the filing date of this invention for implementation.
[0023] Example 1: AI-based de novo design and screening of peptides targeting the AGPS PTS2 domain. 1. Target sequence selection and PTS2 core motif confirmation The sequence of the AGPS protein (Mus musculus) is as follows: MAEAAAGEAGASERDPDAGRARRRLRVLSGHLLGRPQEAPSTNECKARRAASAAGASPAATPAAPESGT IPK KRQEVMKWNGWGYNDSKFLLNKKGQVELTGKRYPLSGLVLPTLRDWIQNTLGVSLEHKTTSKTSINPSEAPPSIVNEDFLQELKEARISYSQEADDRVFRAHGHCLHEIFLLREGMFERIPDIVVWPTCHDVVKIVNLACKY NLCIIPIGGGTSVSYGLMCPADETRTIISLDTSQMNRILWVDENNLTAHVEAGITGQDLERQLKESGYCTGHEPDSLEFSTVGGWISTRASGMKKNIYGNIEDLVVHMKMVTPRGVIEKSSQGPRMSTGPDIHHFIMGSEGTL GVITEATIKIRTPEYQKYGSVAFPNFEQGVACLREIAKQRCAPASIRLMDNQQFQFGHALKPQVSSIFTSFLDGLKKFYITKFKGFDPNQISVATLLFEGDREKVLQHEKQVYDIAAKFGGLAAGEDNGQRGYLLTYVIAYI RDLGLEYYVIGESFETSAPWDRVIDLCRNVKERIRRECKERGVQFAPLSTCRVTQTYDAGACIYFYFAFNYRGISDPLTVFEHTEAAAREEILANGGSLSHHHGVGKIRKQWLKESISDVGFGMLKSVKEYVDPSNIFGNRNLL Note: The single underline represents the PTS2 domain (72 amino acids), and the bold text represents the PTS2 core targeting motif: RLRVLSGHL (SEQ ID NO:2), which is homologous to human and mouse.
[0024] 2. RFdiffusion for de novo generation of candidate peptide backbones For the relatively large and conformationally dynamic PTS2 domain (72 amino acids) of AGPS, a generative AI-based approach was employed, utilizing the RFdiffusion model to generate de novo designed protein binders from Gaussian noise. Through iterative denoising steps, target sequences of 50-80 residues were specifically tailored. The initial generated library contained approximately 1000 candidate sequences.
[0025] 3. AlphaFold3 complex structure prediction and Rosetta interface energy evaluation To ensure optimal druggability and binding fidelity, the initial generated library underwent a stratified screening process. This process integrated AlphaFold3 for three-dimensional structure prediction, forecasting the complex structure of candidate peptides with AGPS-PTS2; subsequently, Rosetta energy analysis was used to calculate the interfacial binding energy. This computational strategy narrowed the library down to three promising candidate molecules: Peptide 224, Peptide 311, and Peptide 391.
[0026] 4. Biophysical experimental verification 4.1 ELISA combined experiment AGPS-PTS2 protein was coated onto an ELISA plate, and serially diluted candidate peptides were added. Binding ability was detected by ELISA. Results showed that Peptide 391 exhibited superior binding ability compared to Peptide 311 and Peptide 224 in the ELISA experiment. Figure 1 ).
[0027] 4.2 Surface Plasmon Resonance (SPR) Analysis The binding kinetics of Peptide 391 and AGPS protein were monitored in real time using SPR technology. AGPS was immobilized on the surface of a sensor chip, and different concentrations of Peptide 391 (50, 100, 200, 400, and 800 nM) were sequentially injected. The SPR response signal increased in a concentration-dependent manner with increasing Peptide 391 concentration. Kinetic curves showed that Peptide 391 binds to AGPS-PTS2, exhibiting a relatively rapid binding and a relatively slow dissociation process. The equilibrium dissociation constant (P391) was obtained after fitting with a kinetic model. The affinity is approximately 100 nM, indicating that Peptide 391 and AGPS-PTS2 have nanomolar-level binding affinity. Figure 2 ).
[0028] 4.3 Micro-thermophoresis (MST) Validation The binding affinity between Peptide 391 and AGPS-PTS2 was independently verified using MST. Fluorescently labeled AGPS-PTS2 protein was incubated with serially diluted Peptide 391, and the migration of the fluorescent molecules within the micro-temperature gradient was detected. With increasing Peptide 391 concentration, the MST response exhibited a typical concentration-dependent S-shaped change. Nonlinear fitting of the binding curves using the law of mass action yielded an equilibrium dissociation constant (Kd) of 120.4 nM for Peptide 391 and AGPS-PTS2. Figure 3 ).
[0029] 4.4 Molecular docking simulation Molecular docking simulations further elucidated the structural basis of the interaction between Peptide 391 and AGPS-PTS2. The results showed that Peptide 391 binds to the PTS2 region of AGPS through multiple hydrogen bonds and salt bridges. Specifically, CYS-5, LYS-6, and ASN-8 form hydrogen bonds with the key AGPS residue ARG-24, LEU26 forms a hydrogen bond with AGPS's HIS-31, and GLU-9 forms hydrogen bonds and a salt bridge with AGPS's ARG-20, collectively forming a stable binding interface. Figure 4 ).
[0030] 5. Leader peptide sequence Pep391 consists of 58 amino acids, with the following amino acid sequence: SCDWCKYNENLVVTGAVDCSLRGWDLRNVRQPVFELGLHTYAIRRVKFSPFHASVLAS (SEQ ID NO:1). This peptide was synthesized by Wuhan Jinsi Biotechnology Co., Ltd.
[0031] Example 2: Verification of the effect of Pep391 in inhibiting AGPS peroxisome translocation 1. Materials PMVSMC cells: Primary vascular smooth muscle cells from mice were isolated and cultured from the thoracic aorta of C57BL / 6 mice using conventional enzymatic digestion. The purity was greater than 90% as determined by α-SMA immunofluorescence. Cells from passages 3 to 7 were used for experiments.
[0032] 2. Experimental Design and Methods 2.1 Experimental Design To evaluate the effect of the AGPS translocation repressor peptide Pep391 on the translocation of AGPS to the peroxisome, PMVSMC cells were randomly divided into the following two groups: Vehicle group: cells were cultured routinely without Pep391 treatment, and an equal volume of solvent as the Pep391 group was added as a control. Pep391 group: After cells were cultured to a suitable degree of confluence, the AGPS translocation inhibitory peptide Pep391 was added at a final concentration of 5 μM and treated continuously for 24 h. All cell groups were cultured under the same conditions, ensuring consistent treatment time, cell density, and solvent concentration. Cells were immediately collected after Pep391 treatment for the separation of cytoplasmic and peroxisome components.
[0033] 2.2 Extraction of cytoplasmic and peroxisome components Equal amounts of PMVSMC cells were collected from each group using a cell scraper. The cell pellet was resuspended in pre-cooled peroxisome extract (5 mM MOPS, pH 7.65, containing 0.25 M sucrose, 1 mM EDTA, 0.1% ethanol and a mixture of protease inhibitors) and then mechanically homogenized.
[0034] The homogenate was first centrifuged at 1,000 ×g for 10 min at 4 °C, and the supernatant was collected. The supernatant was then centrifuged at 2,000 ×g for 10 min at 4 °C to remove larger organelles and mitochondrial components. The resulting supernatant was further centrifuged at 25,000 ×g for 20 min at 4 °C, and the supernatant was collected as the cytoplasmic component, while the precipitate was collected as the crude peroxisomal component. The crude peroxisomal precipitate was resuspended in peroxisomal extract and then ultracentrifuged at 100,000 ×g for 1.5 h at 4 °C, and the precipitate was collected as the peroxisomal component.
[0035] 2.3 Western blot detection of AGPS subcellular distribution Proteins were extracted from the cytoplasm and peroxisome components of each group, and after determining the protein concentration, equal amounts of protein were used for Western blot analysis. The expression level of AGPS in different subcellular components was detected using an AGPS antibody. GAPDH was used as an internal control for the cytoplasmic component, and PMP70 was used as an internal control for the peroxisome component.
[0036] The relative expression levels of AGPS / GAPDH in the cytoplasmic fraction and AGPS / PMP70 in the peroxisome fraction were calculated, and the distribution changes of AGPS in the cytoplasm and peroxisomes were further compared.
[0037] 3. Results and Analysis Compared with the Vehicle group, Pep391 treatment significantly reduced the AGPS protein level in the peroxisome component, while relatively increasing the AGPS level in the cytoplasmic component (Table 1), suggesting that Pep391 can effectively inhibit the translocation / introduction of AGPS from the cytoplasm to the peroxisome.
[0038] Table 1: Relative protein expression levels of AGPS (peroxosomal component / peroxosomal + cytoplasmic component)
[0039] Compared with the Vehicle group, P<0.0001.
[0040] Example 3: Evaluation of the efficacy of Pep391 in treating vascular calcification associated with chronic kidney disease 1. Materials This experiment used SPF-grade male C57BL / 6 mice, aged 6-8 weeks and weighing approximately 18-22g, purchased from Shulaibao Biotechnology Co., Ltd., and housed in the animal facility of Tongji Medical College, Huazhong University of Science and Technology (room temperature 22±3℃; humidity 50±5%, 12h light / dark cycle, free access to food and water). After a week of acclimatization feeding, the animals were randomly divided into 4 groups of 6 mice each, as detailed below: ①Sham surgery + sham treatment group (Sham + Vehicle group): sham surgery + blank control intervention; ②Sham surgery + treatment group (Sham + Pep391 group): sham surgery + Pep391 intervention.
[0041] ③ Surgery + Sham Treatment Group (CKD + Vehicle Group): 5 / 6 nephrectomy + high phosphorus diet + blank control intervention.
[0042] ④ Surgery + Treatment Group (CKD + Pep391 Group): 5 / 6 nephrectomy + high phosphorus diet + Pep391 intervention.
[0043] The feeding and handling of mice were strictly carried out in accordance with the requirements of the US NIH and the animal welfare regulations of the Animal Management Committee of Tongji Medical College, Huazhong University of Science and Technology.
[0044] 2. Methods 2.1 Establishment of a mouse model of vascular calcification associated with chronic kidney disease A CKD-related vascular calcification model was induced by nephrectomy combined with a high-phosphorus diet.
[0045] Week 1: Left Nephrectomy in Mice After weighing, mice were anesthetized with an intraperitoneal injection of tribromoethanol (0.2 mL / 10 g mouse body weight). Their respiratory status was constantly monitored. After anesthesia, the fur on the left side of the mouse's abdomen was shaved, and the mouse was fixed in a prone position. The shaved area was disinfected with iodine. A 1 cm skin incision was made parallel to the spine in the lower left abdomen, and the muscle layer was cut about 1 cm away from blood vessels to expose the abdominal cavity. The left kidney was dissected and freed along the incision using a glass needle. The renal capsule was peeled off, and the renal pedicle (including renal vessels) was double-ligated with 4-0 sutures. The left kidney was completely removed, avoiding the ligation lines, and the remaining renal pedicle tissue was returned to the abdominal cavity. 200 μL of antibiotics was injected intraperitoneally. The muscle and skin layers were sutured layer by layer. 200 μL of saline was injected subcutaneously into the mouse's neck for rehydration. After surgery, the mouse was placed on a heating pad for warmth. Once the mouse regained consciousness, it was transferred to a rearing cage. For the next 24 hours post-surgery, the mouse's respiratory rate and heart rate were closely monitored to ensure unobstructed breathing.
[0046] Week 2: Right nephrectomy (2 / 3 removal) in mice After weighing, mice were anesthetized by intraperitoneal injection of tribromoethanol (0.2 mL / 10 g mouse body weight). All hair on the right side of the mouse's abdomen was shaved, and the mouse was fixed in a prone position. The shaved area was routinely disinfected with povidone-iodine. A 1 cm incision was made in the lower right abdomen, parallel to the spine, cutting through approximately 1 cm of muscle layer, avoiding blood vessels, to fully expose the abdominal cavity. 200 μL of antibiotics was pre-injected into the abdominal cavity. Using a glass dissecting needle, tissues were dissected layer by layer along the incision, fully freeing and dissecting the right kidney. The visceral capsule was removed, and the upper and lower poles of the kidneys were ligated with 4-0 surgical sutures to reduce bleeding during nephrectomy. After removing the upper and lower poles of the right kidney sequentially, absorbable hemostatic gel sponges were applied to the kidney wound. Once the wound was completely hemostatic, the remaining kidney tissue and the hemostatic sponges were returned to the abdominal cavity. Subsequently, the muscle and skin layers were sutured layer by layer, and 200 μL of physiological saline was injected subcutaneously into the mouse's neck for fluid resuscitation. After the surgery, the mouse was kept warm on a heating pad until it was fully awake, and then transferred to a rearing cage for routine care. Within 24 hours after surgery, the mouse's respiratory rate and heart rate were monitored, and the mouse's airway was kept clear.
[0047] Weeks 3 to 6: Mice were fed a diet containing 1% high phosphorus.
[0048] Weeks 7 to 14: Mice were fed a diet containing 2% high phosphorus.
[0049] 2.2 Drug administration Mice were given Vehicle or Pep391 (tail vein injection) at 1 ug / g body weight, twice a week for 12 weeks, one week after nephrectomy.
[0050] 2.3 Sample Collection Serum sample collection: After anesthetizing the mice, orbital blood was collected from the mice and placed in 1.5 mL EP tubes, with approximately 1 mL of blood collected from each mouse. The EP tubes containing blood were left to stand at room temperature for 3-4 hours until serum was observed to separate naturally. The blood samples were then centrifuged at 3000 rpm for 10 minutes, and the clear serum supernatant was transferred to clean EP tubes. All samples were labeled, and finally, the samples were frozen at -20°C for subsequent experimental testing.
[0051] Tissue sample collection: 1) Sample perfusion: Mice were euthanized by cervical dislocation to fully expose the thoracic and abdominal cavities. The right atrial appendage was ruptured, and pre-cooled PBS buffer was slowly perfused through the left ventricle. Perfusion was continued until the mouse liver tissue decolorized and clear fluid flowed from the right atrial appendage, at which point the perfusion procedure was terminated.
[0052] 2) Aortic Tissue Isolation and Preservation: Complete aortic tissue was meticulously isolated along the mouse spine, encompassing the aortic arch, thoracic aorta, and abdominal aorta. The aortic adventitia was gently dissected using forceps, and approximately 5 mm of aortic arch tissue was harvested and fixed in paraformaldehyde fixative for subsequent paraffin embedding and tissue section analysis. Thoracic and abdominal aortic tissues were isolated separately and aliquoted into different EP tubes. After flash freezing in liquid nitrogen for 15 min, the tubes were transferred to a -80°C cryogenic freezer for subsequent detection of target gene mRNA and protein expression levels. Additionally, approximately 3 mm of vascular tissue from the thoracic-abdominal aortic junction was separately aliquoted and preserved for subsequent vascular calcium deposition detection.
[0053] 3) Kidney tissue collection and fixation: Collect mouse kidney tissue, gently remove the kidney capsule of the sham-operated group mice, and fix the intact kidney tissue in paraformaldehyde fixative; carefully remove the connective tissue, intestines and other impurities adhering to the surface of the kidney of the surgical group mice, clean the remaining kidney tissue, and fix it in paraformaldehyde fixative for later use.
[0054] 2.4 Detection Indicators and Methods Corresponding detection methods were used to measure the indicators of each sample to assess the renal function and the degree of vascular and renal pathological damage in mice: the renal function level was evaluated by detecting the levels of creatinine and urea nitrogen in mouse serum; Von Kossa staining was used to stain aortic arch tissue sections to observe and assess the degree of vascular calcification; Western blotting was used to detect the protein expression levels of RUNX2 and BGLAP, markers of abdominal aortic calcification, to further corroborate the phenotypic changes of vascular calcification; a calcium salt detection kit was used to quantitatively detect the calcium deposition content in vascular tissue to accurately assess the level of vascular calcification; Masson staining and Sirius red staining were used to stain kidney tissue sections to comprehensively assess the degree of fibrosis in mouse kidney tissue.
[0055] 3. Results and Analysis 1) Effects of Pep391 on renal function in CKD mice Renal function tests showed that compared with the Sham+Vehicle group, the serum creatinine and blood urea nitrogen levels in the CKD+Vehicle group were significantly increased, with statistically significant differences. Compared with the Sham+Pep391 group, the serum creatinine and blood urea nitrogen levels in the CKD+Pep391 group were also significantly increased, with statistically significant differences. However, there were no significant differences in serum creatinine and blood urea nitrogen levels between the CKD+Pep391 group and the CKD+Vehicle group (Table 2). Masson staining and Sirius red staining were used to detect the level of renal fibrosis in mice. The results showed that the degree of renal fibrosis in the CKD+Vehicle group was significantly more severe than that in the Sham+Vehicle group, and the renal fibrosis in the CKD+Pep391 group was also significantly more severe than that in the Sham+Pep391 group. However, compared with the CKD+Vehicle group, the degree of renal fibrosis in the CKD+Pep391 group did not show significant improvement, and there were no significant differences between the groups (Table 3). The above results indicate that the CKD model was successfully constructed and that Pep391 does not affect the kidney function of CKD mice.
[0056] Table 2: Serum creatinine and blood urea nitrogen levels in mice
[0057] Compared with the Sham+Vehicle group, P<0.0001; Compared with the Sham+Pep391 group, ####P<0.0001.
[0058] Table 3: Masson staining and Sirius red staining
[0059] 2) Effects of Pep391 on vascular calcification in CKD mice Von Kossa silver staining reagent was used to stain mouse aortic arch tissue sections, and stained images were acquired under a microscope. The area of vascular calcification was quantitatively analyzed using ImageJ software. Results showed that compared to the Sham+Vehicle group, the calcified area of the aorta in the CKD+Vehicle group was significantly larger; compared to the Sham+Pep391 group, the calcified area of the vascular calcification in the CKD+Pep391 group was also significantly increased; however, compared to the CKD+Vehicle group, the calcified area of the vascular calcification in the CKD+Pep391 group was significantly smaller (Table 4). These results indicate that vascular calcification was successfully induced in CKD mice, and Pep391 can effectively alleviate vascular calcification lesions.
[0060] Table 4: Relative area of Von Kossa staining in mouse blood vessels
[0061] Compared with the Sham+Vehicle group, P<0.0001; compared with the Sham+Pep391 group, ####P<0.0001; compared with the CKD+Vehicle group, &&&P<0.001.
[0062] 3) Effects of Pep391 on the expression levels of proteins related to vascular calcification phenotype in CKD mice Total protein was extracted from the abdominal aorta tissue of mice, and the expression levels of vascular calcification marker proteins RUNX2 and BGLAP were detected by Western blotting (WB). Protein quantification results showed that compared with the Sham+Vehicle group, the expression levels of RUNX2 and BGLAP proteins in the abdominal aorta tissue of mice in the CKD+Vehicle group were significantly upregulated; compared with the Sham+Pep391 group, the expression levels of these two calcification-related proteins were also significantly increased in the CKD+Pep391 group. However, compared with the CKD+Vehicle group, the expression levels of RUNX2 and BGLAP proteins in the abdominal aorta of mice in the CKD+Pep391 group were significantly decreased (Table 5). These results indicate that Pep391 can effectively inhibit and alleviate CKD-mediated vascular calcification by downregulating the expression of calcification marker proteins.
[0063] Table 5: Expression levels of RUNX2 and BGLAP proteins
[0064] Compared with the Sham+Vehicle group, P<0.0001; compared with the Sham+Pep391 group, ####P<0.0001; compared with the CKD+Vehicle group, &&&&P<0.0001.
[0065] 4) Effects of Pep391 on vascular calcium deposition levels in CKD mice After modeling, vascular tissue of approximately 3 mm in length from the junction of the thoracic and abdominal arteries of mice was collected. The tissue was thoroughly lysed with 0.6 M hydrochloric acid solution, and the prepared tissue homogenate was incubated at 4 ℃ with uniform shaking for at least 24 h. Subsequently, the calcium salt deposition content in the vascular tissue was quantitatively determined using a calcium salt detection kit. The results showed that compared with the Sham+Vehicle group, the CKD+Vehicle group had significantly increased vascular calcium salt deposition; compared with the Sham+Pep391 group, the CKD+Pep391 group also showed significantly increased vascular calcium salt deposition levels. However, compared with the CKD+Vehicle group, the CKD+Pep391 group showed significantly decreased vascular calcium salt deposition levels (Table 6). These results further confirm that Pep391 can effectively alleviate vascular calcification damage in CKD model mice.
[0066] Table 6: Calcium deposition levels in mouse blood vessels
[0067] Compared with the Sham+Vehicle group, P<0.0001; compared with the Sham+Pep391 group, ####P<0.0001; compared with the CKD+Vehicle group, &&&&P<0.0001.
[0068] Key terminology explanation: AGPS (alkylglycerone phosphate synthase) is a key enzyme located on the peroxisome, catalyzing the rate-limiting step in ether lipid biosynthesis. AGPS participates in phospholipid synthesis, maintaining cell membrane structure, redox homeostasis, and signal transduction. Abnormal expression, activity, or subcellular localization of AGPS can lead to lipid metabolism disorders and participate in pathological processes such as tumors, inflammation, neurological diseases, and cardiovascular injury. The enzymatic activity of AGPS is strictly dependent on its efficient translocation to the peroxisome, a process guided by its N-terminal PTS2 signal.
[0069] PTS2 (peroxisomal targeting signal type 2) is a targeting signal located at the N-terminus of some peroxisome matrix proteins, typically composed of a conserved nonapeptide motif. In this invention, the core nonapeptide motif of AGPS's PTS2 is RLRVLSGHL. PTS2 is recognized by the cytoplasmic receptor PEX7 and, with the participation of co-receptors and the peroxisome membrane translocation mechanism, guides cargo proteins into the peroxisome, thereby ensuring the normal progress of related lipid metabolism and redox reactions. The PTS2 domain of AGPS consists of 72 amino acids, and this region is homologous to both humans and mice.
[0070] PKCη (PRKCH gene-encoded protein kinase Cη): a serine / threonine protein kinase. Previous studies in this invention have found that in chronic kidney disease-associated vascular calcification, the translocation of AGPS into the peroxisome depends on the binding of PKCη to AGPS-PTS2. PKCη can mediate the phosphorylation of a conserved serine residue (Ser6, corresponding to Ser42 in the full-length AGPS) in the PTS2 motif, thereby triggering the peroxisome translocation of AGPS.
[0071] Ether lipids are a unique class of glycerophospholipids synthesized in peroxisomes, with their biosynthetic pathway synergistically mediated by AGPS, GNPAT, and FAR1. Ether lipids are essential for membrane structural integrity and cell signaling, but their abnormal accumulation can provide substrates for lipid peroxidation, thereby sensitizing cells to ferroptosis.
[0072] Ferroptosis: a form of regulated cell death driven by iron-dependent lipid peroxidation. Ferroptosis has been shown to be involved in the pathological process of vascular calcification. In this invention, AGPS provides substrates for lipid peroxidation through the synthesis of ether lipids, thereby inducing ferroptosis in vascular smooth muscle cells and driving calcification.
[0073] Vascular smooth muscle cells (VSMCs) are the main cell type of the vascular media. Under conditions of uremia and hyperphosphatemia, systolic VSMCs lose lineage markers (such as SM22α and α-SMA), acquire an osteoblast-like phenotype, and express osteogenic regulatory factors such as RUNX2 and BGLAP. They are the core cellular events driving medial calcification.
[0074] RUNX2: Runt-related transcription factor 2, a key transcription factor for osteogenic differentiation, is an important marker of osteogenic transdifferentiation of vascular smooth muscle cells.
[0075] BGLAP: Osteocalcin, a non-collagenous bone matrix protein secreted by osteoblasts, is a hallmark of osteoblast-like phenotype and vascular calcification.
[0076] α-SMA: α-smooth muscle actin, a marker of the contractile phenotype of vascular smooth muscle cells. Downregulation of its expression suggests that VSMCs are transitioning from a contractile to an osteoblastic phenotype.
[0077] PMP70: 70 kDa peroxisome membrane protein, a marker of peroxisomes used to identify peroxisome components and assess peroxisome abundance.
[0078] GAPDH: Glyceraldehyde-3-phosphate dehydrogenase, an internal reference protein for cytoplasmic components, used for normalization of cytoplasmic components in Western blot.
[0079] RFdiffusion model: A protein structure generation AI based on a diffusion model. Its working principle is similar to "drawing from noise": given a random, meaningless protein structure (noise), a neural network is used to gradually "de-noise" it, transforming it into a reasonable protein or peptide structure that can stably bind to a specific target (such as AGPS). This is the core tool for generating candidate peptide sequences and initial structures.
[0080] AlphaFold3 is the latest version of a protein structure prediction AI developed by DeepMind. Its outstanding capability is the ability to predict the three-dimensional structure of complexes formed by proteins and other molecules (such as proteins, peptides, and small molecules) with high accuracy. In this invention, it is used to initially predict whether a designed peptide can form a stable complex with AGPS.
[0081] Rosetta: A powerful software suite for computational biology, considered the gold standard in protein design. It can perform extremely precise binding free energy calculations, simulate atomic-level interactions (hydrogen bonds, hydrophobic interactions, etc.), and select the molecules with the strongest binding affinity from initially screened candidate peptides.
[0082] Binding free energy (ΔG): A thermodynamic parameter that measures the tightness of the bond between two molecules. The larger the negative value (the more negative), the stronger and more stable the bond.
[0083] SPR (Surface Plasmon Resonance): A real-time, label-free biophysical analysis technique. An AGPS (Aspect-Guided Plasmon Resonance Array) is immobilized on a chip surface, and a peptide solution is allowed to flow through the chip. When the peptide binds to the AGPS, it causes a minute change in the refractive index of the chip surface, which is detected in real time. It can accurately determine the binding rate, dissociation rate, and final affinity constant (Kd), and is one of the gold standards for verifying intermolecular interactions. In this invention, SPR measured the Kd of Peptide 391 to be approximately 100 nM.
[0084] MST (Micro Thermophoresis): This experiment analyzes the interaction between small peptides and AGPS-PTS2 by detecting the migration changes of fluorescently labeled molecules in a micro-temperature gradient and calculates the dissociation constant (Kd). This experiment can be used to verify whether direct binding occurs and to quantitatively evaluate binding affinity. In this invention, MST measured the Kd of Peptide 391 to be 120.4 nM.
[0085] Kd (dissociation constant): A parameter that measures the affinity between two molecules; the smaller the value, the tighter the bond. In this invention, the Kd of Peptide 391 and AGPS-PTS2 is approximately 100–120.4 nM, which is considered nanomolar level high affinity.
[0086] Vehicle (solvent control group): The same volume of solvent (excluding Pep391) as the Pep391 group was given as a blank control to eliminate the influence of the solvent itself on the experimental results.
[0087] Sham group: Mice that underwent only surgical incision and suturing but not nephrectomy were used to exclude the influence of the surgical procedure itself on the experimental results.
Claims
1. An AGPS peroxisome delivery inhibitory peptide, the amino acid sequence of which is shown in SEQ ID NO:
1.
2. A pharmaceutical composition comprising the inhibitory peptide of claim 1 and a pharmaceutically acceptable carrier and / or excipient.
3. The pharmaceutical composition according to claim 2, characterized in that: The dosage form of the pharmaceutical composition is an injection.
4. The use of the inhibitory peptide of claim 1 or the pharmaceutical composition of claim 2 or 3 in the preparation of a drug for the prevention or treatment of vascular calcification associated with chronic kidney disease.
5. The application as described in claim 4, characterized in that: The inhibitory peptide reduces osteogenic transformation of vascular smooth muscle cells and / or vascular calcium deposition by inhibiting the translocation or introduction of AGPS protein from the cytoplasm to the peroxisome.
